10 July 2018 - - Cambridge, Massachusetts-based serious and rare disease therapeutics developer Acceleron Pharma Inc. (NASDAQ: XLRN) has appointed Robert K. Zeldin, M.D. as chief medical officer (CMO), the company said.
Zeldin brings to Acceleron more than two decades of clinical, regulatory and industry experience, most recently serving as CMO of Belgium-based Ablynx NV where he was responsible for the medical, regulatory, pharmacovigilance, clinical operations, biostatistics, and data management functions and led a team of 60.
Previously, Zeldin held roles such as senior vice president and head of global clinical development at Stallergenes SA, vice president and US medical franchise head at Novartis Pharmaceuticals, and senior director of clinical development at Merck.
He also served as medical officer at the US FDA's Center for Biologics Evaluation and Research and spent several years in clinical practice treating patients with allergic, asthmatic, and immunologic disorders.
Zeldin holds a B.A. with honors from Johns Hopkins University and an M.D. from Tufts University School of Medicine. His postdoctoral training included Residency in Internal Medicine at University Health Center of Pittsburgh and Fellowship in Allergy and Clinical Immunology at Johns Hopkins University School of Medicine.
Acceleron is focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases.
Its research platform has generated four therapeutic candidates that are currently in clinical trials.